Our Clients Say
“Before working with Northridge Consulting, we had 8 patents and a strong product but struggled to explain our value to partners and get responses. We knew OsteoFuse had real potential but didn’t know where to start / couldn’t seem to break through.”
John R. Cashman. Ph.D.
President and Founder
ABOUT THE CLIENT
Human BioMolecular Research Institute (HBRI) is a nonprofit research institute focused on advancing regenerative medicine and developing new therapies for human diseases through foundational biological and chemical research.
How HBRI Went from Stalled Outreach to a Clear Path to Licensing Partners
a nonprofit regenerative medicine institute case study
The PRODUCT
OsteoFuse, a human stem cell-derived next-generation autograft replacement for spinal fusion
The Challenge.
HBRI had built a strong foundation - eight issued patents in stem cell technology and genuinely promising science. What they lacked was a path to market. No licensing partner had been identified, and no program had advanced toward IND-stage development. Outreach had stalled, targets were unclear, and previous attempts to engage partners had gone nowhere.
The Work.
Defined and solidified buyer personas for two key partner profilesDeveloped distinct value propositions tailored to each personaArticulated the product benefits of OsteoFuse in partner-facing languageCreated an executive summary to anchor outreach and meetingsWrote targeted email messaging designed to open doors with licensing prospects
Defined and solidified buyer personas for two key partner profiles
Developed distinct value propositions tailored to each persona
Articulated the product benefits of OsteoFuse in partner-facing language
Created an executive summary to anchor outreach and meetings
Wrote targeted email messaging designed to open doors with licensing prospects
The Outcome.
HBRI moved from an unfocused outreach effort to a structured, compelling go-to-market approach — with the right messaging, for the right audiences, delivered through the right materials. They are now positioned to pursue licensing partnerships with clarity and confidence as OsteoFuse advances through the FDA process.